XML 83 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Results from Discontinued Operations The financial results of the Chemicals business are classified as discontinued operations in the accompanying Consolidated Statements of Comprehensive Income for all periods presented. Results from discontinued operations are as follows:
in millions202420232022
Pretax loss$(10.2)$(14.7)$(25.2)
Income tax benefit2.6 3.9 6.6 
Loss on discontinued operations, net of tax$(7.6)$(10.8)$(18.6)
Schedule of Depreciation, Depletion, Accretion and Amortization Expense
Depreciation, depletion, accretion and amortization expense for the years ended December 31 is outlined below:
in millions202420232022
Depreciation$464.6 $441.1 $409.1 
Depletion59.5 61.1 50.2 
Accretion14.7 13.9 14.1 
Depreciation of finance leases9.5 12.8 16.5 
Amortization of intangibles83.9 88.1 97.6 
Total depreciation, depletion, accretion and amortization$632.2 $617.0 $587.5 
Schedule of Fair Value Measurement on Recurring Basis
Our assets at December 31 subject to fair value measurement on a recurring basis are summarized below:
in millions20242023
Level 1 Fair Value
Rabbi Trust
Mutual funds$31.1 $31.7 
Total$31.1 $31.7 
Level 2 Fair Value
Interest rate swaps$0.0 $(0.3)
Rabbi Trust
Money market mutual fund0.3 0.5 
Total$0.3 $0.2 
Schedule of Liabilities Under Self-Insurance Program The following table outlines our self-insurance program at December 31:
dollars in millions20242023
Self-insurance Program
Self-insured liabilities (undiscounted)$138.2 $151.7 
Insured liabilities (undiscounted)2.3 2.3 
Discount rate4.22 %4.56 %
Amounts Recognized in Consolidated Balance Sheets
Investments and long-term receivables2.3 2.3 
Other current liabilities(47.3)(59.6)
Other noncurrent liabilities(74.6)(76.1)
Net insurance liabilities (discounted)$(119.6)$(133.4)
Schedule of Estimated Payments (Undiscounted) Under Self-Insurance Program
Estimated payments (undiscounted and excluding the impact of related receivables) under our self-insurance program for the five years subsequent to December 31, 2024 are as follows:
in millions
Estimated Payments under Self-insurance Program
2025$40.1 
202629.0 
202717.6 
202810.0 
20295.4 
Schedule of Unrecognized Compensation Expense
A summary of the estimated future compensation cost (unrecognized compensation expense) as of December 31, 2024 related to share-based awards granted to employees under our long-term incentive plans is presented below:
dollars in millionsUnrecognized
Compensation
Expense		Expected
Weighted-Average
Recognition (Years)
SOSARs 1
$1.7 1.4
Performance shares18.6 1.7
Restricted shares13.4 1.7
Total/weighted-average$33.7 1.7
1Stock-Only Stock Appreciation Rights (SOSARs)
Schedule of Pretax Compensation Expense
Pretax compensation expense related to our employee share-based compensation awards and related income tax benefits for the years ended December 31 are summarized below:
in millions202420232022
Pretax compensation expense$50.6 $60.6 $38.7 
Income tax benefits7.7 9.1 6.9 
Schedule of Weighted-Average Common Shares Outstanding Assuming Dilution
Earnings per share are computed by dividing net earnings by the weighted-average common shares outstanding (basic EPS) or weighted-average common shares outstanding assuming dilution (diluted EPS), as set forth below:
in millions202420232022
Weighted-average common shares outstanding132.3133.0133.0
Dilutive effect of
SOSARs0.20.20.2
Other stock compensation awards0.60.50.4
Weighted-average common shares outstanding, assuming dilution133.1133.7133.6
Schedule of Antidilutive Common Stock Equivalents The number of antidilutive common stock equivalents for which the exercise price exceeds the weighted-average market price for the years ended December 31 is as follows:
in millions202420232022
Antidilutive common stock equivalents0.00.00.1